BIOTEST AG VZBIOTEST AG VZBIOTEST AG VZ

BIOTEST AG VZ

No trades
See on Supercharts
Market capitalization
‪1.40 B‬EUR
‪127.00 M‬EUR
‪684.60 M‬EUR
Beta (1Y)
0.02

About BIOTEST AG VZ

CEO
Peter Janssen
Headquarters
Dreieich
Website
Employees (FY)
‪2.43 K‬
Founded
1946
ISIN
DE0005227235
FIGI
BBG00HMXTFY3
Biotest AG engages in the development, manufacture, and marketing of plasma proteins and biotherapeutic drugs. It operates through the following segments: Therapy, Plasma and Services, and Other. The Therapy segment develops and produces blood plasma-based immunoglobulins, clotting factors, and albumins which are used to treat diseases of the immune system, haematological diseases, and in intensive care medicine. The Plasma and Services segment includes the areas of plasma sales and contract manufacturing. The Other segment refers to the merchandise business. The company was founded by Carl Adolf Schleussner and Hans Schleussner in 1946 and is headquartered in Dreieich, Germany.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of BIO3 is 29.0 EUR — it has increased by 0.35% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on VIE exchange BIOTEST AG VZ stocks are traded under the ticker BIO3.
BIOTEST AG VZ is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
BIO3 stock is 0.35% volatile and has beta coefficient of 0.02. Check out the list of the most volatile stocks — is BIOTEST AG VZ there?
Yes, you can track BIOTEST AG VZ financials in yearly and quarterly reports right on TradingView.
BIO3 stock hasn't changed in a week, the month change is a 8.21% rise, over the last year BIOTEST AG VZ has showed a 8.81% decrease.
BIO3 net income for the last quarter is ‪38.60 M‬ EUR, while the quarter before that showed ‪86.60 M‬ EUR of net income which accounts for −55.43% change. Track more BIOTEST AG VZ financial stats to get the full picture.
Today BIOTEST AG VZ has the market capitalization of ‪1.14 B‬, it has decreased by 1.26% over the last week.
Like other stocks, BIO3 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOTEST AG VZ stock right from TradingView charts — choose your broker and connect to your account.
BIO3 reached its all-time high on Oct 18, 2021 with the price of 43.9 EUR, and its all-time low was 17.4 EUR and was reached on Mar 16, 2020.
See other stocks reaching their highest and lowest prices.
As of Apr 24, 2024, the company has ‪2.43 K‬ employees. See our rating of the largest employees — is BIOTEST AG VZ on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOTEST AG VZ technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOTEST AG VZ stock shows the sell signal. See more of BIOTEST AG VZ technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.